This summary is intended to provide a snapshot of the original research. It is in no way a substitute for the original research article, nor is it intended to be a complete reflection of the original research.
Originally published in JACC Clin Electrophysiol.,18 January 2023
This randomised control trial compared the effectiveness and safety of Hybrid Ablation (HA) and Catheter Ablation (CA) in treating persistent atrial fibrillation (persAF).
In a 12-month prospective, randomized trial of 41 ablation-naive patients, HA demonstrated higher freedom from atrial tachyarrhythmias off antiarrhythmic drugs (89% vs. 41%).
Both procedures had comparable safety profiles with few complications. HA, combining thoracoscopic epicardial and transvenous endocardial approaches, proved to be an efficacious and safe alternative, suggesting better outcomes than CA for persistent AF treatment.
ClinicalTrials.gov Identifier: NCT02441738
Disclaimer
This article is compiled from various resources researched and compiled by the contributor. It is in no way presented as an original work. Every effort has been made to attribute quotes and content correctly. Where possible, all information has been independently verified. The Medical Education Network bears no responsibility for any inaccuracies which may occur from the use of third-party sources. If you have any queries regarding this article contact us
Fact-checking Policy
The Medical Education Network makes every effort to review and fact-check the articles used as source material in our summaries and original material. We have strict guidelines in relation to the publications we use as our source data, favouring peer-reviewed research wherever possible. Every effort is made to ensure that the information contained here is an accurate reflection of the original material. Should you find inaccuracies, out of date content or have any additional issues with our articles, please make use of the contact us form to notify us.